ClinicalTrials.gg
CompletedNCT04521114NASHUpdated Mar 1, 2023Results posted

Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

A Phase 2 interventional study of Placebo and leronlimab 700 mg in Nonalcoholic Steatohepatitis (NASH), sponsored by CytoDyn, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-01.

Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
174th of 460
87 · median 56
Started
2020
with 38 others
Phase 2
192 of 547
15 open now
Registered
318th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 174th largest by enrollment of the 460 interventional ones that give a count, is one of 39 that started in 2020, is one of 192 in phase 2, and was the 318th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This is a phase II study of of Leronlimab (PRO 140)-Humanized monoclonal antibody to CCR5 in patients with Nonalcoholic Steatohepatitis (NASH).

Read the detailed description

This is an exploratory phase II, multi-center, two-part study (Part 1: randomized, placebo-controlled, two-arm with 60 patients; Part 2: non-randomized, single-arm, open-label with 30 patients) designed to evaluate the safety and efficacy of leronlimab after subcutaneous (SC) administration in patients with NASH for 13 weeks.

A Follow Up visit was conducted 28 (± 3) days after receiving the last study treatment (i.e., after last dose of Leronlimab (PRO 140) or placebo.

03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH)

Keywords

  • NASH
  • PRO 140
  • Leronlimab
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Subjects are required to meet ALL of the following criteria for enrollment into the study:

  1. Subject is a male or female between 18 to 75 years of age inclusive.
  2. Evidence of nonalcoholic steatohepatitis (NASH) based on one of the following criteria:

    • Criteria 1: -confirmed diagnosis of NASH on a liver , or
    • Criteria 2: FibroScan or Shearwave US during screening (or within 6 months before screening) shows kPa ≥7 but \<14 and CAP ≥260.
  3. Subject shows presence of hepatic fat fraction as defined by ≥ 8% on MRI-PDFF and cT1 ≥ 800 ms at Screening.
  4. Has had a stable body weight (±5%) within 6 months prior to Screening.
  5. (BMI) ≥ 28 kg/m2 at Screening
  6. Has clinically normal resting 12-lead at Screening Visit or, if abnormal, considered not by the Principal Investigator.
  7. Laboratory Screening results as indicated below:

    1. :ALT Ratio ≤ 1, if AST or ALT value is >
    2. Screening Liver enzymes (AST, ALT, and ALK PHOS) \< 5 x ULN.
    3. Total ≤ 1.3 mg/dL (except if Gilbert's Disease)
    4. count ≥ 150,000/mm3
    5. (INR) \< 1.3
    6. Estimated (eGFR) ≥ 60/mL/min
    7. Glycosylated () \< 9%.
    8. Thyroid-Stimulating Hormone (TSH) within normal reference range. Note: Any subject with a non-clinically significant TSH value outside of the normal range may be enrolled if their T3 and free T4 values are within the normal range.
  8. Subjects with pre-diabetes or type 2 diabetes will be allowed to participate if the following criteria is met:

    • Subjects who are taking anti-diabetic medications should be on a stable dose for a period of at least 3 months prior to Screening and do not anticipate clinically significant dose adjustments during the course of study.
    • Subjects must be on a stable diet/lifestyle regimen for at least 3 months prior to screening and do not anticipate a clinically significant change during the course of study.
  9. Subjects who are taking Vitamin E should be on a stable dose of Vitamin E (if ≥ 400 IU) for a period of at least 4 weeks prior to Screening and do not anticipate dose adjustments for the duration of the study.
  10. Both male and female patients and their partners of must agree to use two medically accepted methods of (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], or one of the following methods of birth control (intrauterine devices, tubal sterilization or vasectomy) or must practice complete abstinence from intercourse of from study entry to 6 months after the last day of treatment (excluding women who are not of childbearing potential and men who have been sterilized).
  11. Females of child-bearing potential must have a negative serum pregnancy test at Screening Visit and negative urine pregnancy test prior to receiving the first dose of study drug; and Male participants must agree to use contraception and refrain from donating sperm for at least 90 days after the last dose of study intervention.
  12. Subject is willing and able to give prior to any study specific procedures being performed.
  13. Subject is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures and study restrictions

Exclusion Criteria: Subjects meeting ANY of the following criteria will be excluded from enrollment:

  1. Any concurrent clinically significant liver disease with an etiology other than NASH including hepatitis, alcoholic hepatitis, hypoxic/ischemic hepatopathy, and biliary tract disease.
  2. History of alcohol consumption greater than 21/units/week (for males) and 14/units/week (for females) within the last 2 years prior to screening.

    Note: Use of online unit calculator for alcohol consumption is recommended (e.g., https://alcoholchange.org.uk/alcohol-facts/interactive-tools/unit-calculator)

  3. Any drug-induced steatohepatitis secondary to amiodarone, , estrogens, methotrexate, tetracycline, or other medications known to cause hepatic steatosis.
  4. Undergone major surgery, including liver surgery, within 6 months prior to screening deemed clinically significant by the investigator.
  5. Prior or pending liver transplantation.
  6. History or presence of cirrhosis or stage 4 fibrosis in historical liver biopsy and/or hepatic decompensation including ascites, hepatic encephalopathy or variceal bleeding.
  7. Active (defined as having a positive hepatitis B surface antigen [HBsAg] test), (defined as having a positive Anti-HCV test with detectable reflex HCV RNA; Note: Subject with positive Anti-HCV test and with undetectable HCV RNA would not be excluded), acute hepatitis A (defined as subjects with serum positive for hepatitis A IgM (HAV) antibody) or acute hepatitis E (defined as having anti-HEV IgM antibody).
  8. Any active infection requiring systemic therapy at the time of screening, which is considered clinically significant per the Investigator.
  9. Positive test for (HIV) or HIV infection.
  10. History of bleeding diathesis within 6 months of screening.
  11. Any within the past 5 years, excluding successfully treated basal cell carcinoma or squamous cell carcinoma without evidence of .
  12. Seizure disorder requiring ongoing antiseizure therapy or with any condition that, in the judgment of the investigator, is likely to increase the risk of seizure (e.g. CNS malignancy)
  13. Clinically significant active cardiac disease which would interfere with study conduct or study results interpretation per the PI.
  14. Any known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  15. Prior therapy with Leronlimab or any other CCR5 antagonist (e.g. maraviroc) within 6 months prior to screening.
  16. History of severe allergic, anaphylactic, or other reactions to humanized monoclonal antibodies.
  17. Any condition requiring continuous systemic treatment with (such as corticosteroids) or immunomodulatory medications.

    Note: Inhaled or topical steroids of up to 5 mg daily prednisone equivalent dose are permitted in the bsence of active autoimmune disease.

  18. History of administration of a live, attenuated vaccine within four weeks prior to start of PRO 140 treatment or anticipation that such a will be required during the remainder of the study.

    Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed. However intranasal influenza vaccines (e.g., Flu-Mist ®) are live attenuated vaccines, and are not allowed.

  19. Currently participating in an study or received an investigational drug within 28 days or 5 half-lives (whichever is longer) prior to study drug administration
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Leronlimab 700 mg

    Leronlimab 700 mg SC weekly injection

    Drug: leronlimab 700 mg

  • Experimental
    Leronlimab 350 mg

    Leronlimab 350 mg SC weekly injection

    Drug: leronlimab 350 mg

  • Placebo comparator
    Placebo

    Placebo SC weekly injection

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo will be administered subcutaneously every week for 13 weeks.

  • 700 mg leronlimab will be administered subcutaneously every week for 13 weeks.

    Also known as: PRO 140

  • 350 mg leronlimab will be administered subcutaneously every week for 13 weeks.

    Also known as: PRO 140

06

What researchers measure

Primary outcomes

  1. MRI-PDFF Change From Baseline to Week 14

    Change in hepatic fat fraction from baseline assessed by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) at week 14

    Time frame: Change from baseline (day one, first day of treatment) to EOT (day 92, 13 weeks of treatment)

Secondary outcomes

  1. MRI-cT1 Change From Baseline to Week 14

    MRI corrected T1 (cT1) is emerging as a promising quantitative surrogate metric for assessing a composite of liver inflammation and fibrosis.

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

  2. Alkaline Phosphatase

    Change from Baseline to Week 14 in Alkaline Phosphatase

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

  3. Alanine Aminotraferase (ALT)

    Change from Baseline to Week 14 in Alanine Aminotraferase (ALT)

    Time frame: Measured at baseline (day 1) and at day 92

  4. Aspartate Aminotransferase (AST)

    Change from Baseline to Week 14 in Aspartate Aminotransferase (AST)

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

  5. GGT S

    Change from Baseline to Week 14 in Gamma Glutamyl transferase, GGT S

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

  6. Neutrophils/Leukocytes

    Change in Neutrophils/Leukocytes ratio from Baseline to Week 14

    Time frame: Measured at baseline (day 1, start of treatment) and at EOT (day 92)

  7. CCL2

    Change from Baseline to Week 14 in Monocyte Chemotactic Protein 1 (CCL2)

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

  8. CCL3

    Change from Baseline (day 1, start of treatment) to Week 14 (EOT) in Macrophage Inflammatory Protein 1 Alpha

    Time frame: Measured at baseline (day 1, start of treatment) and at EOT (day 92)

  9. CCL5 (Rantes)

    Change from Baseline to Week 14 in CCL-5 (Rantes)

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

  10. Fibro Test Score

    Change from baseline (day 1, start of treatment) to Week 14 (EOT) in Fibro Test Score measured on a scale of 0 to 1, where 0 to 0.27 is no fibrosis, 0.27 to 0.48 is minimal fibrosis, 0.48 to 0.58 is moderate fibrosis, 0.58 to 0.74 is advanced fibrosis and 0.74 to 1.00 is severe fibrosis (Cirrhosis). Minimum score is zero, maximum score (worst outcome) is 1.

    Time frame: Measured at baseline (day 1, start of treatment) and at EOT (day 92)

  11. CCL11( Eotaxin-1)

    Change from Baseline to Week 14 in Eosinophils Chemotactic Protein

    Time frame: Measured at baseline (day 1, start of treatment) and at EOT (day 92)

  12. CCL18

    Change from Baseline to week 14 in CCL18 (Pulmonary \& Activation-Reg Chemokine)

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

  13. VCAM

    Change from Baseline to Week 14 in Vascular Cell Adhesion Molecule 1

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

  14. Interleukin-1 Beta

    Change from Baseline to Week 14 in Interleukin-1 Beta

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

  15. IL-1RA

    Change from Baseline to Week 14 in Interleukin 1 Receptor Antagonist

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

  16. IL-6

    Change from Baseline to Week 14 in Interleukin 6

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

  17. IL-8

    Change from Baseline to Week 14 in Interleukin 8

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

  18. TNF Receptor 2

    Change from baseline (day 1, start of treatment) to Week 14 (EOT) in Tumor Necrosis Factor Receptor 2

    Time frame: Measured at baseline (day 1, start of treatment) and at EOT (day 92)

  19. TIMP-1

    Change from Baseline (day 1, start of treatment) to Week 14 (EOT) in Tissue Inhibitor of Metalloproteinases 1 (ng/mL)

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

  20. En Rage

    Change from baseline (start of treatment, day 1) to Week 14 (EOT) in En Rage (Receptor Advanced Glycation End-Products)

    Time frame: Measured at baseline (day 1) and at EOT (day 92)

07

Results

Posted Mar 1, 2023

Participant flow

Participant flow — Overall Study
MilestoneLeronlimab 700 mgLeronlimab 350 mgPlacebo
Started302730
Completed242128
Not completed662
Withdrew: Lost to follow-up120
Withdrew: Withdrawal by subject122
Withdrew: Adverse event100
Withdrew: Sponsor wish100
Withdrew: Withdrawal of consent220

Outcome measures

PrimaryMRI-PDFF Change From Baseline to Week 14

Change in hepatic fat fraction from baseline assessed by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) at week 14

Time frame:
Change from baseline (day one, first day of treatment) to EOT (day 92, 13 weeks of treatment)
Reported as:
Median · Percentage of hepatic fat fraction
MRI-PDFF Change From Baseline to Week 14
Percentage of hepatic fat fractionLeronlimab 700 mgLeronlimab 350 mgPlacebo
MRI-PDFF Change From Baseline to Week 14-1.25 (-2.60 to 2.30)-0.90 (-3.10 to 0.40)0.90 (-0.20 to 3.70)
SecondaryMRI-cT1 Change From Baseline to Week 14

MRI corrected T1 (cT1) is emerging as a promising quantitative surrogate metric for assessing a composite of liver inflammation and fibrosis.

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Median · Milliseconds (ms)
MRI-cT1 Change From Baseline to Week 14
Milliseconds (ms)Leronlimab 700 mgLeronlimab 350 mgPlacebo
MRI-cT1 Change From Baseline to Week 14-7.0 (-35.0 to 22.0)-2.00 (-54.00 to 24.00)22.0 (2.0 to 41.0)
SecondaryAlkaline Phosphatase

Change from Baseline to Week 14 in Alkaline Phosphatase

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Mean · IU/L
Alkaline Phosphatase
IU/LLeronlimab 700 mgLeronlimab 350 mgPlacebo
Alkaline Phosphatase0.37 ± 7.77-3.68 ± 7.99-0.83 ± 7.75
SecondaryAlanine Aminotraferase (ALT)

Change from Baseline to Week 14 in Alanine Aminotraferase (ALT)

Time frame:
Measured at baseline (day 1) and at day 92
Reported as:
Mean · U/L
Alanine Aminotraferase (ALT)
U/LLeronlimab 700 mgLeronlimab 350 mgPlacebo
Alanine Aminotraferase (ALT)4.77 ± 32.06-0.76 ± 16.651.79 ± 18.83
SecondaryAspartate Aminotransferase (AST)

Change from Baseline to Week 14 in Aspartate Aminotransferase (AST)

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Mean · U/L
Aspartate Aminotransferase (AST)
U/LLeronlimab 700 mgLeronlimab 350 mgPlacebo
Aspartate Aminotransferase (AST)1.40 ± 15.10-6.12 ± 33.332.17 ± 13.23
SecondaryGGT S

Change from Baseline to Week 14 in Gamma Glutamyl transferase, GGT S

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Mean · U/L
GGT S
U/LLeronlimab 700 mgLeronlimab 350 mgPlacebo
GGT S5.67 ± 14.12-3.00 ± 14.730.90 ± 11.61
SecondaryNeutrophils/Leukocytes

Change in Neutrophils/Leukocytes ratio from Baseline to Week 14

Time frame:
Measured at baseline (day 1, start of treatment) and at EOT (day 92)
Reported as:
Mean · Ratio of neutrophils to leukocytes
Neutrophils/Leukocytes
Ratio of neutrophils to leukocytesLeronlimab 700 mgLeronlimab 350 mgPlacebo
Neutrophils/Leukocytes0.93 ± 5.94-4.32 ± 8.420.55 ± 6.07
SecondaryCCL2

Change from Baseline to Week 14 in Monocyte Chemotactic Protein 1 (CCL2)

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Mean · pg/mL
CCL2
pg/mLLeronlimab 700 mgLeronlimab 350 mgPlacebo
CCL257.60 ± 175.98-77.0 ± 161.99-38.57 ± 140.75
SecondaryCCL3

Change from Baseline (day 1, start of treatment) to Week 14 (EOT) in Macrophage Inflammatory Protein 1 Alpha

Time frame:
Measured at baseline (day 1, start of treatment) and at EOT (day 92)
Reported as:
Mean · pg/mL
CCL3
pg/mLLeronlimab 700 mgLeronlimab 350 mgPlacebo
CCL31.40 ± 6.22-7.20 ± 5.03-0.96 ± 2.62
SecondaryCCL5 (Rantes)

Change from Baseline to Week 14 in CCL-5 (Rantes)

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Mean · ng/mL
CCL5 (Rantes)
ng/mLLeronlimab 700 mgLeronlimab 350 mgPlacebo
CCL5 (Rantes)8.14 ± 15.82-6.80 ± 44.40-0.39 ± 8.28
SecondaryFibro Test Score

Change from baseline (day 1, start of treatment) to Week 14 (EOT) in Fibro Test Score measured on a scale of 0 to 1, where 0 to 0.27 is no fibrosis, 0.27 to 0.48 is minimal fibrosis, 0.48 to 0.58 is moderate fibrosis, 0.58 to 0.74 is advanced fibrosis and 0.74 to 1.00 is severe fibrosis (Cirrhosis). Minimum score is zero, maximum score (worst outcome) is 1.

Time frame:
Measured at baseline (day 1, start of treatment) and at EOT (day 92)
Reported as:
Mean · score on a scale
Fibro Test Score
score on a scaleLeronlimab 700 mgLeronlimab 350 mgPlacebo
Fibro Test Score0.02 ± 0.060.01 ± 0.07-0.00 ± 0.06
SecondaryCCL11( Eotaxin-1)

Change from Baseline to Week 14 in Eosinophils Chemotactic Protein

Time frame:
Measured at baseline (day 1, start of treatment) and at EOT (day 92)
Reported as:
Mean · pg/mL
CCL11( Eotaxin-1)
pg/mLLeronlimab 700 mgLeronlimab 350 mgPlacebo
CCL11( Eotaxin-1)29.30 ± 87.67-3.88 ± 95.10-41.32 ± 116.25
SecondaryCCL18

Change from Baseline to week 14 in CCL18 (Pulmonary \& Activation-Reg Chemokine)

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Mean · ng/mL
CCL18
ng/mLLeronlimab 700 mgLeronlimab 350 mgPlacebo
CCL186.77 ± 36.16-27.28 ± 40.49-2.14 ± 34.43
SecondaryVCAM

Change from Baseline to Week 14 in Vascular Cell Adhesion Molecule 1

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Mean · ng/mL
VCAM
ng/mLLeronlimab 700 mgLeronlimab 350 mgPlacebo
VCAM35.93 ± 178.64-82.80 ± 79.958.89 ± 109.96
SecondaryInterleukin-1 Beta

Change from Baseline to Week 14 in Interleukin-1 Beta

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Mean · pg/mL
Interleukin-1 Beta
pg/mLLeronlimab 700 mgLeronlimab 350 mgPlacebo
Interleukin-1 Beta0.06 ± 0.310.09 ± 0.460.16 ± 0.61
SecondaryIL-1RA

Change from Baseline to Week 14 in Interleukin 1 Receptor Antagonist

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Mean · pg/mL
IL-1RA
pg/mLLeronlimab 700 mgLeronlimab 350 mgPlacebo
IL-1RA6.37 ± 125.39-16.24 ± 74.4015.93 ± 54.63
SecondaryIL-6

Change from Baseline to Week 14 in Interleukin 6

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Mean · pg/mL
IL-6
pg/mLLeronlimab 700 mgLeronlimab 350 mgPlacebo
IL-60.17 ± 1.18-0.24 ± 0.680.31 ± 1.74
SecondaryIL-8

Change from Baseline to Week 14 in Interleukin 8

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Mean · pg/mL
IL-8
pg/mLLeronlimab 700 mgLeronlimab 350 mgPlacebo
IL-8-3.25 ± 8.89-2.18 ± 7.81-0.54 ± 5.00
SecondaryTNF Receptor 2

Change from baseline (day 1, start of treatment) to Week 14 (EOT) in Tumor Necrosis Factor Receptor 2

Time frame:
Measured at baseline (day 1, start of treatment) and at EOT (day 92)
Reported as:
Mean · pg/mL
TNF Receptor 2
pg/mLLeronlimab 700 mgLeronlimab 350 mgPlacebo
TNF Receptor 21.04 ± 3.25-1.66 ± 2.240.79 ± 1.72
SecondaryTIMP-1

Change from Baseline (day 1, start of treatment) to Week 14 (EOT) in Tissue Inhibitor of Metalloproteinases 1 (ng/mL)

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Mean · ng/mL
TIMP-1
ng/mLLeronlimab 700 mgLeronlimab 350 mgPlacebo
TIMP-18.30 ± 32.39-11.76 ± 29.331.25 ± 25.62
SecondaryEn Rage

Change from baseline (start of treatment, day 1) to Week 14 (EOT) in En Rage (Receptor Advanced Glycation End-Products)

Time frame:
Measured at baseline (day 1) and at EOT (day 92)
Reported as:
Mean · ng/mL
En Rage
ng/mLLeronlimab 700 mgLeronlimab 350 mgPlacebo
En Rage30.77 ± 229.87-60.40 ± 245.3254.96 ± 141.75

Adverse events

Collected over 14 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leronlimab 700 mg0/30 (0%)2/30 (6.7%)28/30 (93.3%)
Leronlimab 350 mg1/27 (3.7%)1/27 (3.7%)21/27 (77.8%)
Placebo0/30 (0%)2/30 (6.7%)21/30 (70%)
Most frequent serious events
Most frequent serious events
EventLeronlimab 700 mgLeronlimab 350 mgPlacebo
ACCIDENTInjury, poisoning and procedural complications0/301/270/30
TOOTH ABSCESSGastrointestinal disorders0/300/271/30
EYE INFECTION BACTERIALInfections and infestations1/300/270/30
INVASIVE DUCTAL BREAST CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/300/270/30
RENAL IMPAIRMENTRenal and urinary disorders0/300/271/30
Most frequent other events
Showing 10 of 18
Most frequent other events
EventLeronlimab 700 mgLeronlimab 350 mgPlacebo
C-reactive protein increasedInvestigations7/308/273/30
Abdominal PainGastrointestinal disorders5/302/274/30
DiarrhoeaGastrointestinal disorders5/302/272/30
Urinary tract infectionRenal and urinary disorders5/303/273/30
HyperglycaemiaEndocrine disorders4/300/271/30
HypertensionVascular disorders2/303/271/30
Injection site painInjury, poisoning and procedural complications3/301/272/30
Blood Creatine Phosphokinase IncreasedInvestigations1/301/273/30
HypercalcaemiaMetabolism and nutrition disorders3/300/271/30
Alanine aminotransferase increasedInvestigations0/302/272/30

Baseline characteristics

Patients with Nonalcoholic Steatohepatitis (NASH)

Age, Continuous
Age, Continuous(years)Leronlimab 700 mgLeronlimab 350 mgPlaceboTotal
Age53.2 ± 13.6852.4 ± 8.3855.6 ± 10.4753.80 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Leronlimab 700 mgLeronlimab 350 mgPlaceboTotal
Female1913941
Male11142146
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Leronlimab 700 mgLeronlimab 350 mgPlaceboTotal
Hispanic or Latino16161244
Not Hispanic or Latino14111843
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Leronlimab 700 mgLeronlimab 350 mgPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0527
White30222880
More than one race0000
Unknown or Not Reported0000
BMI
BMI(kg/m^2)Leronlimab 700 mgLeronlimab 350 mgPlaceboTotal
Mean41.2 ± 9.5638.0 ± 5.5238.4 ± 5.8939.2 ± 7.33
08

Study locations

7 sites
  • Southern California Research Center
    Coronado, California 92118, United States
  • Meridien Research
    Maitland, Florida 32751, United States
  • Floridian Clinical Research
    Miami Lakes, Florida 33016, United States
  • Sensible Healthcare, LLC
    Ocoee, Florida 34761, United States
  • Center for Advanced Research & Education
    Gainesville, Georgia 30501, United States
  • Care United Research LLC
    Forney, Texas 75126, United States
  • American Research Corporation
    San Antonio, Texas 78215, United States
09

References and documents

Publications

  • Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, Trauner M, Romero Gomez M, Oliveira C, Day C, Dufour JF, Bellentani S, Ngo Y, Traussnig S, Perazzo H, Deckmyn O, Bedossa P, Ratziu V, Poynard T; FLIP Consortium and the FibroFrance Group. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment Pharmacol Ther. 2016 Oct;44(8):877-89. doi: 10.1111/apt.13770. Epub 2016 Aug 23. PubMed 27549244 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Dec 2021, 12 months.

Results were first posted in Mar 2023, 1 year 2 months after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 12 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2019
First posted
Aug 20, 2020
StartActual
Dec 1, 2020
Primary completionActual
Dec 29, 2021
CompletionActual
Dec 29, 2021
Results first posted
Mar 1, 2023
Last update
Mar 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04521114
Lead sponsor
CytoDyn, Inc.
Responsible party
Sponsor
First posted
Aug 20, 2020
Start date
Dec 1, 2020
Primary completion
Dec 29, 2021
Completion
Dec 29, 2021
Results posted
Mar 1, 2023
Last update
Mar 1, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion